Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor-Reference-Cited by-同舟云学术

Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor

Published:2001-12 Issue:12 Volume:36 Page:1781-1784
ISSN:0022-3468
Container-title:Journal of Pediatric Surgery
language:en
Short-container-title:Journal of Pediatric Surgery

Author:

Soffer Samuel Z.,Kim Eugene,Moore James T.,Huang Jianzhong,Yokoi Akiko,Manley Christina,O'Toole Kathleen,Middlesworth William,Stolar Charles,Yamashiro Darrell,Kandel Jessica

Publisher

Elsevier BV

Subject

General Medicine,Pediatrics, Perinatology and Child Health,Surgery

Reference9 articles.

1. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms tumor;Rowe;J Pediatr Surg,2000

2. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents;Kerbel;Bioessays,1991

3. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug resistant cancer;Browder;Cancer Research,2000

4. Tumor resistance to alkylating agents conferred by mechanism operative only in vivo;Teisher;Science,1990

5. Camptothecins: A review of their development and schedules of administration;O'Leary;Eur J Cancer,1998

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment problem of anephric patients with Wilms tumor;Russian Journal of Pediatric Hematology and Oncology;2020-07-04

2. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models;Clinical Cancer Research;2015-12-30

3. Treatment of relapsed Wilms tumour (WT) patients: Experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG);Pediatric Blood & Cancer;2014-12-29

4. FAK Inhibition Abrogates the Malignant Phenotype in Aggressive Pediatric Renal Tumors;Molecular Cancer Research;2014-01-24

5. Metronomic Chemotherapy in Pediatric Malignancies;Metronomic Chemotherapy;2014